A Randomized, Open-label, Parallel-group, Single-dose, Biocomparability Study of the Pharmacokinetics of Belatacept Drug Products Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Active Pharmaceutical Ingredient Manufactured by Process C in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Belatacept (Primary)
- Indications Renal transplant rejection
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 24 Feb 2017 Status changed from recruiting to completed.
- 06 Oct 2016 Planned End Date changed to 1 Jan 2017.
- 06 Oct 2016 Planned primary completion date changed to 1 Jan 2017.